We analyzed data from the Multi MERCI, TREVO, and TREVO 2 trials, in which the Merci Retriever (Stryker Neurovascular, Mountain View, CA) and the Trevo Retriever (Stryker Neurovascular) were used.4 (link),6 (link),8 (link) The databases of all 3 trials were maintained at Stryker Neurovascular. Appropriate institutional review board or ethics committees approvals were obtained by participating centers in all 3 trials. All 3 trials enrolled patients with acute ischemic stroke who were either ineligible for or refractory to IV tPA. Endovascular thrombectomy therapy was initiated within 8 hours of symptom onset.
All 3 trials included patients with angiographically confirmed intracranial vessel occlusion in both anterior and posterior circulations. All patients were older than 18 years with National Institutes of Health Stroke Scale (NIHSS) score of greater than 8. The TREVO and TREVO 2 trials had age limit of 85 years and NIHSS score upper limit of 30 and 29, respectively. In the Multi MERCI trial, IV tPA was allowed within 3 hours after symptom onset. A 4.5-hour time window was used for IV tPA in the TREVO and TREVO 2 trials.
All 3 trials included patients with angiographically confirmed intracranial vessel occlusion in both anterior and posterior circulations. All patients were older than 18 years with National Institutes of Health Stroke Scale (NIHSS) score of greater than 8. The TREVO and TREVO 2 trials had age limit of 85 years and NIHSS score upper limit of 30 and 29, respectively. In the Multi MERCI trial, IV tPA was allowed within 3 hours after symptom onset. A 4.5-hour time window was used for IV tPA in the TREVO and TREVO 2 trials.
